KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Capital Leases (2023 - 2025)

Historic Capital Leases for Castle Biosciences (CSTL) over the last 3 years, with Q3 2025 value amounting to $339000.0.

  • Castle Biosciences' Capital Leases rose 1730.1% to $339000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $339000.0, marking a year-over-year increase of 1730.1%. This contributed to the annual value of $311000.0 for FY2024, which is 114400.0% up from last year.
  • Castle Biosciences' Capital Leases amounted to $339000.0 in Q3 2025, which was up 1730.1% from $364000.0 recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Capital Leases ranged from a high of $364000.0 in Q2 2025 and a low of $25000.0 during Q4 2023
  • Over the past 3 years, Castle Biosciences' median Capital Leases value was $312000.0 (recorded in 2024), while the average stood at $281142.9.
  • Per our database at Business Quant, Castle Biosciences' Capital Leases soared by 114400.0% in 2024 and then soared by 1666.67% in 2025.
  • Quarter analysis of 3 years shows Castle Biosciences' Capital Leases stood at $25000.0 in 2023, then soared by 1144.0% to $311000.0 in 2024, then increased by 9.0% to $339000.0 in 2025.
  • Its Capital Leases was $339000.0 in Q3 2025, compared to $364000.0 in Q2 2025 and $328000.0 in Q1 2025.